Is Orchard Therapeutics plc (ORTX) a Buy, Sell, or Hold?
Orchard Therapeutics plc
NASDAQ:ORTX
$16.7 USD
$0.05 (0.3%)
- Volume
- 372.35K
- Average Volume
- 92.98K
- Market Capitalization
- $380.11M
- P/E Ratio
- -27.38
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $16.72
- Year Low
- $4.24
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.78
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Hubert Baburaj Gaspar |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ORTX |
| CUSIP | 68570P200 |
| CIK | 0001748907 |
| Web | https://www.orchard-tx.com |
| Phone | 44 20 3 808 8286 |
| Currency | USD |
| Employees | 166 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | 0.59 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.78 |
| Quick Ratio | 2.72 |
| Cash Ratio | 1.13 |
Sales & Book Value
| Annual Sales | $6.99M |
| Price / Sales | 54.41 |
| Cash Flow | -6.45 |
| Price / Cash Flow | -4.61 |
| Price / Book | 2.17 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.61 |
| Trailing P/E Ratio | -27.38 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | $-7.88M |
| Net Margin | -112.84% |
| Pretax Margin | -129.00% |
| Return on Equity | -5.12% |
| Return on Assets | -3.60% |
Financials Score
| AltmanZ Score | -3.29 |
| Piotroski Score | 5.00 |
| Working Capital | 104.55M |
| Total Assets | 202.27M |
| Ebit | 48.98M |
| Market Cap | 380.11M |
| Total Liabilities | 122.01M |
Poll Results
About Orchard Therapeutics plc (NASDAQ:ORTX) Stock
Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disea ... se, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
2026-04-30 02:30:00
Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United Kingdom Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United Kingdom
Frequently Asked Questions
-
What is the current Orchard Therapeutics plc (ORTX) stock price?
-
Orchard Therapeutics plc(NASDAQ:ORTX) stock price is $16.7 in the last trading session. During the trading session, ORTX stock reached the peak price of $16.72 while $4.24 was the lowest point it dropped to. The percentage change in ORTX stock occurred in the recent session was 0.3% while the dollar amount for the price change in ORTX stock was $0.05.
-
ORTX's industry and sector of operation?
-
The NASDAQ listed ORTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ORTX?
-
Frank E. Thomas | President & Chief Operating Officer
Benjamin Navon | Director of Corporation Communications
Fulvio Mavilio | Chief Scientific Officer
Hubert Baburaj Gaspar | Chief Executive Officer, Member of Scientific Advisory Board & Executive Director
Robin Kenselaar | Senior Vice President & GM of EMEA Commercial Operations -
How many employees does ORTX have?
-
Number of ORTX employees currently stands at 166. ORTX operates from 108 Cannon Street, London, None EC4N 6EU, GB.
-
Link for ORTX official website?
-
Official Website of ORTX is: https://www.orchard-tx.com
-
How do I contact ORTX?
-
ORTX could be contacted at phone #44 20 3 808 8286 and can also be accessed through its website. ORTX operates from 108 Cannon Street, London, None EC4N 6EU, GB.
-
How many shares of ORTX are traded daily?
-
The average number of ORTX shares traded daily for last 3 months was 92.98K.
-
What is the market cap of ORTX currently?
-
The market value of ORTX currently stands at $380.11M with its latest stock price at $16.7